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INTRODUCTION
Coronary artery calcium score (CACS) was developed to quan-
tify the extent of coronary calcification. Clinically, it is a surro-
gate marker for the degree of atherosclerotic plaque burden. 
CACS is an independent predictor of coronary events and im-
proves cardiovascular risk prediction in asymptomatic patients.1,2 
As such, the current 2013 American College of Cardiology/Am-
erican Heart Association (ACC/AHA) guidelines recommend 
CACS as an additional screening tool for cardiovascular risk 
stratification, and define individuals with a CACS ≥300 Agatston 
units (AU) as high risk.3
A member of the interleukin (IL)-1 receptor family, ST2 is an 
emerging biomarker for cardiovascular disease (CVD), espe-
cially in response to mechanical stress.4 Its expression in car-
diomyocytes is upregulated in response to mechanical stretch, 
and has been demonstrated to be a new biomarker for heart 
failure.5-7 The membrane-bound form of ST2 interacts with IL-
33 and can reduce atherosclerosis development, whereas sol-
uble ST2 (sST2), a decoy receptor for IL-33, enhances athero-
sclerotic plaques in ApoE knock-out mice.8 These animal ex-
periments suggested that ST2 plays an important role in vas-
cular biology. Recent data from the Framingham Heart Study 
(FHS) showed that elevated sST2 concentrations predict both 
incident hypertension and changes in blood pressure (BP) typi-
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cally seen with aging.9 Building on this study, the FHS group ex-
amined the association between sST2 and subclinical athero-
sclerosis in order to elucidate the underlying relationship bet-
ween the ST2/IL-33 pathway and vascular biology.10 However, 
no significant association between sST2 and carotid intima 
medial thickness (IMT) or plaques was found. Currently, no 
studies have investigated the association between sST2 and 
CACS, another marker for atherosclerosis. In the present study, 
we evaluated associations between serum sST2 levels and 
CACS and compared the abilities of sST2 and high sensitive 
C-reactive protein (hsCRP) to predict high risk CACS in a com-
munity-based Korean cohort for the first time.
 
MATERIALS AND METHODS
Study participants
The Mapo study is a community-based cohort study that was 
initiated to investigate the prevalence, correlation, and pro-
gression of subclinical CVD. The study cohort comprises resi-
dents from Mapo-gu, a metropolitan district within Seoul, Ko-
rea, who visited a public health center for a routine health 
check-up. In the Mapo cohort study, men aged ≥45 years and 
women aged ≥55 years were enrolled and screened for sub-
clinical atherosclerosis using CACS. 
In the present study, we enrolled 456 individuals (285 men, 
66.5±5.8 years) who were registered in Mapo-gu cohort be-
tween January 2011 and March 2013. Subjects were divided 
into two groups according to CACS. Selection was determined 
using an arbitrary cut-off CACS of 100 AU. We selected 228 in-
dividuals with a CACS of more than 100 AU and 228 age- and 
gender-matched individuals with a CACS of less than 100 AU. 
The Institutional Review Board at Yonsei University College of 
Medicine approved the study (4-2014-0754), and all partici-
pants gave informed consent. 
 
Clinical and anthropometric measurements
All individuals underwent a baseline evaluation including an 
initial standardized questionnaire. Height, weight, body mass 
index (BMI), anthropometric data, and BP were measured. 
Total, low-density lipoprotein (LDL) and high-density lipopro-
tein (HDL) cholesterol, triglycerides, and glucose levels were 
measured from blood samples obtained after a 12-hour fast. 
hsCRP was measured as previously described.11 Smoking was 
defined as current or former smoker. Dyslipidemia was de-
fined as any of the following: high total cholesterol (>200 mg/
dL), high LDL-cholesterol (>160 mg/dL), low HDL-cholesterol 
(<40 mg/dL for men, <50 mg/dL for women), and/or high tri-
glycerides (>150 mg/dL), or current use of lipid-lowering thera-
py. Participants were considered to have diabetes mellitus 
(DM) if they reported a history of DM and/or were receiving 
anti-diabetic treatment or had a fasting plasma glucose level of 
at least 126 mg/dL. Hypertension was defined as a self-report-
ed history of hypertension, a history of antihypertensive med-
ication use, and/or a BP of 140/90 mm Hg or more at the time 
of the visit. 
Measurement of coronary artery calcium
All examinations were performed using a 320-row CT system 
(Aquilion ONE; Toshiba Medical Systems, Tokyo, Japan) with 
patients in the supine position, and were acquired during a 
single breath hold, which allows for image reconstruction at a 
single cardiac phase. Dual scanograms were used for planning 
the examination and determining the anatomical range to be 
covered. A non-enhanced prospective electrocardiogram-gat-
ed scan was performed to measure CACS with the following 
parameters: rotation time of 275 ms, slice width of 3.0 mm, tube 
voltage of 120 kV, and tube current using the Sure Exposure 
3D® (Tochigi, Japan) with an automatic exposure control sys-
tem. CACS was assessed on a postprocessing workstation (Vit-
rea fX, version 6.4; Vital Images, Minnetonka, MN, USA) using 
calcium score analysis software (VScore; Vital Images). Coro-
nary scans were used to identify each focus of calcification 
with a minimal density of 130 Hounsfield units and a minimal 
voxel size of 1.03 mm3 along the course of the coronary artery.12 
Agatston calcium scores were calculated to quantify the extent 
of coronary artery calcification.13
Measurement of sST2
sST2 concentrations were measured in blood samples (serum) 
collected after an 12-hour fast, and immediately centrifuged 
for storage at -80°C. sST2 concentrations were measured us-
ing a high-sensitivity sandwich immunoassay (Presage ST2; 
Critical Diagnostics, San Diego, CA, USA). The performance 
characteristics of this assay have been recently described.14 The 
assay has a lower detection limit of 2 ng/mL, and meets accept-
able analytical performance criteria, exhibiting an average co-
efficient of variation of 2.85% for intra-assay and 6.74% for in-
ter-assay variation in our study.
Statistical analysis
Continuous variables are summarized as a mean±standard de-
viation, and categorical variables are summarized as a percent-
age of the group total. Variables not in the normal distribution 
were log transformed for analysis. Continuous variables were 
compared using independent t-tests or Mann-Whitney U test 
for non-normally distributed variables. Pearson’s correlation 
analysis or Spearman test for non-normally distributed vari-
ables was used to determine simple correlation between con-
tinuous variables. A multivariate logistic regression analysis 
was conducted using all variables significantly correlated with 
CACS. The net reclassification improvement (NRI) and inte-
grated discrimination index (IDI) for sST2 over hsCRP (and vice 
versa) was calculated, and the area under the receiver operat-
ing characteristic (ROC) curves (AUC) of sST2 and hsCRP were 
compared using STATA version 13.0 (Stata Corp LP, College 
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Station, TX, USA). A two-tailed p value <0.05 was considered 
statistically significant. All other statistical analyses were per-
formed with SPSS version 21.0 software (SPSS/IBM Corp., Chi-
cago, IL, USA).
RESULTS
Clinical characteristics and laboratory findings 
Baseline characteristics of study participants are summarized 
in Table 1. The mean age, BMI, and systolic BP (SBP) were 66±6 
years old, 25.2±2.9 kg/m2, and 124.2±14.9 mm Hg, respectively. 
Serum levels of sST2 ranged from 10.7 to 197.6 (median 27.9, 
interquartile range 22.2–35.4) ng/mL. Mean CACS was 237.2± 
465.0 AU, and there were 99 (21.7%) subjects with a CACS ≥300 
AU. Patients with a CACS ≥300 AU were considered as high 
risk. There was a significant difference in hsCRP (1.27±1.95 mg/L 
vs. 2.90±9.00 mg/L for high risk patients, p=0.002) (Fig. 1A). 
No difference was observed in sST2 in this same high risk pop-
ulation (29.7±15.2 ng/mL vs. 32.6±12.2 ng/mL for high risk 
CACS, p=0.080) (Fig. 1B) between high risk and non-high risk 
CACS group. Women had a lower waist circumference, SBP, 
smoking history, fasting glucose, gamma glutamyltransferase 
(GGT), and uric acid levels. Women had higher dyslipidemia, 
statin use, total cholesterol, and HDL-cholesterol level. We ob-
served a significant gender difference in serum sST2 levels (33.2± 
16.8 ng/mL vs. 25.4±8.2 ng/mL, for men vs. women, p<0.001). 
However, no difference in CACS and hsCRP were observed be-
tween genders. 
Association of serum levels of sST2 and hsCRP 
Data regarding the association between sST2 or hsCRP levels 
Table 1. Baseline Characteristics of Study Participants 
Men (n=285) Women (n=171) Total (n=456)
Age, yrs 67±6 66±5 66±6
WC, cm 87±7 82±8† 85±8
BMI, kg/m2 25.2±2.7 25.1±3.1 25.2±2.9
SBP, mm Hg 126.0±15.3 121.2±13.8* 124.2±14.9
DBP, mm Hg 69.6±9.8 68.2±8.8 69.1±9.4
HR, /min 74±10 75±9 74±10
Ex/current smoker, n (%) 164/52 (57.5/18.2) 3/3 (1.8/1.8)† 167/55 (36.6/12.1)
Hypertension, n (%) 157 (55.1) 104 (60.8) 261 (57.2)
DM, n (%) 61 (21.4) 30 (17.5) 91 (20.0)
Dyslipidemia, n (%) 63 (22.1) 73 (42.7)† 136 (29.8)
ACEi, n (%) 7 (2.5) 3 (1.8) 10 (2.2)
ARB, n (%) 83 (29.1) 43 (25.1) 126 (27.6)
BB, n (%) 30 (10.5) 11 (6.4) 41 (9.0)
CCB, n (%) 88 (30.9) 50 (29.2) 138 (30.3)
Diuretics, n (%) 108 (17.0) 136 (26.6) 532 (17.2)
Aspirin, n (%) 79 (27.7) 35 (20.5) 114 (25.0)
Statin, n (%) 57 (20.0) 55 (32.2)* 112 (24.6)
Total-C, mmol/L 4.9±0.9 5.1±0.9* 5.0±0.9
TG, mmol/L 3.5±1.9 3.3±1.5 3.4±1.8
LDL-C, mmol/L 2.9±0.9 3.1±0.9 3.0±0.9
HDL-C, mmol/L 1.3±0.4 1.5±14.3† 53.2±14.4
Glucose, mg/dL 106.3±22.8 99.1±17.7† 103.6±21.3
GGT, mg/dL 41.2±36.1 23.0±19.3† 34.4±32.1
Uric acid, mg/dL 5.7±1.3 4.3±0.9† 5.2±1.3
CACS, AU 264±541 192±293 237±465
CACS >100 AU, n (%) 142 (49.8) 87 (50.9) 229 (50.2)
CACS >300 AU, n (%) 69 (24.2) 30 (17.5) 99 (21.7)
hsCRP, mg/L 0.85 (0.52–1.42) 0.75 (0.44–1.39) 0.81 (0.50–1.42)
sST2, ng/mL 30.9 (24.3–37.7) 24.3 (19.3–29.0)† 27.9 (22.2–35.4)
WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; DM, diabetes mellitus; ACEi, ACE 
inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; Total-C, total cholesterol; TG, triglycerides; LDL-C, low-density lipo-
protein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; GGT, gamma glutamyltransferase; CACS, coronary artery calcium score; AU, Agatston units; 
hsCRP, high-sensitivity C-reactive protein; sST2, soluble ST2.
Data are presented as mean±standard deviation or n (%) or median (interquartile range). 
*p value<0.01 compared to men, †p-value<0.001 compared to men.
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and the clinical and laboratory parameters are summarized in 
Table 2. The LDL-cholesterol, alanine transaminase (ALT), cre-
atinine, GGT, uric acid, white blood cell count (WBC), and CACS 
correlated with both sST2 and hsCRP levels. Total-cholesterol, 
glucose, aspartate transaminase (AST), blood urea nitrogen 
(BUN), serum creatinine, phosphate and hemoglobin corre-
lated with only sST2 level, whereas only waist conference, HDL-
cholesterol, and CACS correlated with only hsCRP level. Serum 
log sST2 level significantly correlated with log hsCRP level 
(r=0.128, p=0.006).
 
Comparison of risk stratification of sST2 and hsCRP 
According to current AHA/ACC guidelines, we defined patients 
with a CACS >300 AU to be at high risk. In univariate regres-
sion analysis, both log sST2 [odd ratio (OR) 5.900, 95% confi-
dence interval (CI) 1.471–23.668, p=0.012] and log hsCRP (OR 
2.812, 95% CI 1.600–4.942, p<0.001) were significantly related 
to high CACS group. We compared the risk-stratifying power 
of sST2 and hsCRP in high risk patients using three statistical 
methods. First, using multivariate logistic regression, we com-
pared the association of sST2/hsCRP with being classified as 
high risk (Table 3). After adjusting for other risk factors such as 
age, gender and current smoking status, only log hsCRP was 
significantly associated with high risk CACS (OR 2.450, 95% CI 
1.1336–4.492, p=0.004). When we inserted sST2/hsCRP into the 
adjusted model as categorical variables (lower vs. higher ter-
tile), only hsCRP (OR 1.858, 95% CI 1.051–3.284, p=0.033) cor-
related with a high risk CACS, in line with the multivariate re-
gression analysis. Second, we compared AUC in ROC for high 
risk CACS. In this analysis, we observed no significant differ-
ences between sST2 (AUC 0.596, 95% CI 0.520–0.671) and 
hsCRP (AUC 0.580, 95% CI 0.514–0.647, p for difference=0.64). 
Third, to determine if any additive prognostic value for pre-
dicting high risk CACS was gained by combining sST2 with 
hsCRP, we compared the NRI for sST2 over hsCRP (Table 4). 
The NRI for sST2 over hsCRP was not statistically significant 
(continuous NRI 0.212, 95% CI -0.255–0.453, 20% & 25% risk 
cut-off NRI 0.0790, p=0.140, IDI 0.002, p=0.269). Meanwhile, 
however, the NRI for hsCRP over sST2 was significantly differ-
ent (continuous NRI 0.238, 95% CI 0.001–0.474, 20% & 25% risk 
cut-off NRI 0.139, p=0.055, IDI 0.022, p=0.035). Collectively, 
these data indicated that hsCRP provides superior discrimina-
Table 2. Correlation Analysis with sST2 and hsCRP 
Log sST2 Log hsCRP
R p value R p value
WC, cm 0.038 0.421 0.124 0.008
BMI, kg/m2 -0.022 0.641 -0.061 0.196
SBP, mm Hg 0.025 0.588 0.014 0.763
DBP, mm Hg -0.009 0.855 -0.014 0.759
HR, /min 0.024 0.606 0.027 0.562
Total-C, mmol/L -0.100 0.032 0.086 0.065
TG, mmol/L 0.030 0.517 0.121 0.010
LDL-C, mmol/L -0.101 0.032 0.143 0.002
HDL-C, mmol/L -0.040 0.395 -0.225 <0.001
Glucose, mg/dL 0.139 0.003 0.021 0.655
AST 0.150 0.001 0.062 0.186
ALT 0.161 0.001 0.093 0.047
BUN 0.104 0.026 0.006 0.901
Creatinine 0.222 <0.001 0.172 <0.001
Calcium 0.026 0.577 0.001 0.984
Phosphate -0.232 <0.001 -0.023 0.632
GGT, mg/dL 0.228 <0.001 0.149 0.001
Uric acid, mg/dL 0.155 0.001 0.142 0.002
Hemoglobin, mg/dL 0.163 <0.001 0.080 0.087
WBC 0.226 <0.001 0.333 <0.001
CACS 0.101 0.031 0.101 0.032
Log hsCRP 0.128 0.006
sST2, soluble ST2; WC, waist circumference; BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; Total-C, 
total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholester-
ol; HDL-C, high-density lipoprotein-cholesterol; AST, aspartate transaminase; 
ALT, alanine transaminase; BUN, blood urea nitrogen; GGT, gamma glutamyl-
transferase; WBC, white blood cell count; CACS, coronary artery calcium 
score; hsCRP, high-sensitivity C-reactive protein.
Fig. 1. Mean differences in sST2 (A) and hsCRP (B) between the low and high coronary artery calcium score groups (<300 Agatston units vs. ≥300 Ag-
atston units). *Means p value <0.01 by Mann-Whitney U test between low and high CACS group. sST2, soluble ST2; hsCRP, high sensitive C-reactive pro-
tein; CACS; coronary artery calcium score.
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tion and risk reclassification for high risk CACS, compared to 
sST2. In addition, we chose a different cutoff value of CACS 
(100 or 200 AU) for defining high risk CACS, rather than 300 
AU, although we could not find superiority for sST2 over hsCRP 
for predicting high risk CACS group (data not shown).
 
Subgroup analysis for gender
Given the observed gender differences in sST2 levels, we per-
formed a subgroup analysis according to sex. In correlation 
analysis, in men, log sST2 level was associated with glucose 
(r=0.140, p=0.018), AST (r=0.209, p<0.001), ALT (r=0.185, p= 
0.002), GGT (r=0.193, p=0.001), WBC (r=0.232, p<0.001), and 
log hsCRP (r=0.154, p=0.009). These associations were not ob-
served women, in whom log sST2 level was correlated with SBP 
(r=-0.164, p=0.032) and BUN (r=0.201, p=0.008). We did not 
find any statistical significance in comparing AUC, NRI, and 
IDI in either men or women (data not shown).
DISCUSSION
In the present study, we report a significant association of sST2 
with hsCRP; both sST2 and hsCRP were significantly associat-
ed with CACS in subjects from a community cohort. Also, sST2 
did not improve net reclassification for predicting high risk 
CACS. Overall, hsCRP demonstrated superior discrimination 
and risk reclassification, compared to sST2.
The CACS is a surrogate marker of the degree of atheroscle-
rotic plaque burden and an independent predictor of coronary 
events in asymptomatic patients.1,2 In the Multi-Ethnic Study 
of Atherosclerosis (MESA) study, several cardiovascular risk 
markers were compared for their ability to improve the predic-
tion of incident CVD in an intermediate-risk patient popula-
tion.15 In the study, CACS, ankle-brachial index, hsCRP, and 
family history were independent predictors of incident CVD, 
and CACS provided superior discrimination and risk reclassi-
fication over other risk markers. Reflecting this, the current 
AHA/ACC guidelines recommend using the CACS as an addi-
tional screening tool for cardiovascular risk stratification.3 Con-
sidering the radiation hazard, higher price, and lack of insur-
ance coverage of CACS measurements, biomarker predicting 
high risk CACS can be meaningful and practical in real-world 
clinical settings, especially in Korea. For this reason, in the cur-
rent study, we used CACS as a surrogate marker for CVD risk 
and compared the value of sST2 and hsCRP in predicting high 
CACS.
ST2 is an emerging biomarker for diseases related to inflam-
mation, such as CVD, heart transplant, and graft-versus-host 
disease.16,17 There are two functional ST2 isoforms that have op-
posite roles in immunity. First, a membrane-bound ST2 iso-
form forms a complex with IL-33 and induces type 2 immune 
response and tissue repair. In contrast, the sST2 isoform, sST2, 
appears to work as a decoy receptor and negatively regulates 
IL-33 function.18 A role for inflammation in the initiation and 
progression of atherosclerosis has been well established.19 The 
membrane-bound form of ST2 interacts with IL-33, and this 
interaction can reduce atherosclerosis development. Converse-
ly, sST2 has been shown to enhance atherosclerotic plaques.8 
A recent study from FHS showed that an elevated sST2 concen-
tration predicted incident hypertension, although it was un-
able to indicate the underlying pathophysiologic mecha-
nism(s).9 Following this study, they investigated the association 
between sST2 and subclinical atherosclerosis, such as carotid 
atherosclerosis.10 However, they found no significant associa-
tions of sST2 with carotid IMT and plaque. However, this study 
did not measure CACS. To the best of our knowledge, the cur-
rent study is the first to investigate the possible correlation be-
tween serum sST2 level and CACS, an established marker for 
subclinical atherosclerosis.
In our study, sST2 levels in women were significantly lower 
than those in men (Table 1). This is consistent with a recently 
published study from the FHS.20 In our study, the pattern of 
association of sST2 with other clinical and laboratory param-
eters differed according to gender. In the FHS study, sST2 level 
was correlated with gender (female), age, SBP, use of antihy-
pertensives, and DM. Among these clinical correlates, only fe-
Table 4. Net Reclassification Improvement for High Risk Coronary Artery Calcium Score Group by sST2 and hsCRP 
sST2>hsCRP p value hsCRP>sST2 p value
NRI
Continuous 0.212 (95% CI -0.255–0.453) 0.238 (95% CI 0.001–0.474)
20%/25% risk 0.079 0.140 0.139 0.055
IDI 0.002 0.269 0.022 0.035
sST2, soluble ST2; hsCRP, high-sensitivity C-reactive protein; NRI, net reclassification improvement; IDI, integrated discrimination index; CI, confidence interval.
Table 3. Multivariate Logistic Regression Analysis of Association of High Risk Coronary Artery Calcium Score Group with sST2 and hsCRP
sST2 hsCRP
OR (95% CI) p value OR (95% CI) p value
Log sST2 or hsCRP (1 SD increase) 2.837 (0.608–13.247) 0.185 2.450 (1.336–4.492) 0.004
sST2 or hsCRP (lower vs. higher tertile) 1.261 (0.695–2.289) 0.445 1.858 (1.051–3.284) 0.033
sST2, soluble ST2; hsCRP, high-sensitivity C-reactive protein; OR, odd ratio; CI, confidence interval; GGT, gamma glutamyltransferase.
After adjusting age, sex, current smoking status, hypertension history, statin use, glucose and GGT level.
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male sex was significantly correlated with sST2 levels in our 
study (regression coefficient=-0.259, p<0.001). This discrepan-
cy may results from a number of differences between the cur-
rent study and the FHS study. First, it may result from the dif-
ferences in baseline clinical characteristics. Our study parti-
cipants were older (66 years old vs. 59 years old) and had a 
higher prevalence of hypertension (57% vs. 25–29%) and DM 
(20% vs. 9–12%). Also, our participants had higher cardiovas-
cular risk characteristics, compared to those in FHS. Lastly, we 
cannot rule out that these differences may result from ethnic 
differences in the study populations. Data regarding sST2 in the 
Asian community is sparse. This is especially true in an asymp-
tomatic community rather than heart failure patients. Further 
study is warranted to address this gap in our knowledge.
In our study, although sST2 levels were correlated with 
CACS, they were not predictive of high risk CACS subjects. In 
contrast, hsCRP levels could a high risk CACS, providing su-
perior discrimination and risk reclassification. Previous stud-
ies have also shown the association between hsCRP and CACS. 
In the MESA study, inflammatory markers, such as CRP, IL-6, 
and fibrinogen, were weakly associated with CAC presence 
and burden. The authors of that study suggested that inflam-
matory biomarkers and CAC may reflect a distinct pathophysi-
ology of atherosclerosis.20,21 Also, a recent report from the Lud-
wigshafen Risk and Cardiovascular Health (LURIC) study sh-
owed that sST2 is not associated with coronary angiographic 
disease severity.22 Our data were consistent with these findings. 
Qasim, et al.23 reported a strong gender association for CRP 
with CACS, and based on this, implied that CRP may be more 
useful as a biomarker in women. In a Korean study, the asso-
ciation between CRP and CACS was found to differ according 
to HDL-cholesterol levels.24 We did not observe this gender/
HDL level-specific association in our study (data not shown). 
The lack of an association between sST2 and CACS/carotid 
IMT in the current and previous studies suggest that sST2 may 
not be a biomarker directly associated with vascular patho-
physiology. Rather, increased sST2 may result from other 
pathophysiologic mechanisms, such as increased cardiac load, 
resulting in increased mechanical stretch of the heart, and may 
be more useful to predict hypertension.9,10 Indeed, recent work 
has demonstrated an association between sST2 and left ven-
tricular hypertrophy in hypertensive patients25,26 and a positive 
association between sST2 and carotid-femoral pulse wave ve-
locity.27 Further studies are needed to verify these results. 
Our study was not without limitations. First, the relatively 
small size of the study population limits the power of the study. 
This may, in part, explain the discrepancy between the FHS 
study and our data. Second, this is a cross-sectional observa-
tional study. As such, we are unable to explain any cause and 
effect of the associations. However, this study generates new 
hypotheses for future investigations; larger, prospective, and 
follow-up studies are needed. Third, the study population was 
comprised of relatively old and overweight hypertensive pa-
tients. This may confound the association of sST2 and CACS 
and weaken the associations among sST2, hsCRP, and CACS. 
Therefore, extending our findings to the general population 
should be done with caution. Fourth, we selected individuals 
according to CACS, potentially introducing recruitment bias. 
Lastly, our AUC analysis did not find hsCRP to be superior 
over sST2 for predicting CACS. This may result from our limit-
ed sample size, and thus, a larger study is warranted.
In conclusion, we noted a significant association between 
sST2 and CACS in a community cohort for the first time. Nev-
ertheless, hsCRP demonstrated superior discrimination and 
risk reclassification of CACS, compared with sST2. In this study, 
use of sST2 as a biomarker did not improve the net reclassifi-
cation for predicting high risk CACS. 
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